Of the 4 patients who developed disseminated disease, 2 did not have biallellic CDKN2A loss in their primary or metastatic tumor and 2 had biallelic deletion in a subset of melanocytes that were not present at distant metastatic sites. Here, CDKN2A is linked to metastatic neoplasm.